Rankings
▼
Calendar
INMB Q2 2024 Earnings — INmune Bio, Inc. Revenue & Financial Results | Market Cap Arena
INMB
INmune Bio, Inc.
$35M
Q2 2024 Earnings
Healthcare
Biotechnology
Income Statement
Revenue
$0
-100.0% YoY
Gross Profit
$0
Operating Income
-$10M
Net Income
-$10M
EPS (Diluted)
$-0.50
QoQ Revenue Growth
-100.0%
Cash Flow
Operating Cash Flow
-$8M
Free Cash Flow
-$8M
Stock-Based Comp.
$2M
Balance Sheet
Total Assets
$52M
Total Liabilities
$15M
Stockholders' Equity
$37M
Cash & Equivalents
$31M
Year-over-Year Comparison
Metric
Current
Year Ago
Change
Revenue
$0
$46,000
-100.0%
Gross Profit
$0
$46,000
-100.0%
Operating Income
-$10M
-$6M
-53.9%
Net Income
-$10M
-$7M
-49.9%
← FY 2024
All Quarters
Q3 2024 →